Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle, Donna M. Ambrosino, View ORCID ProfileAndrew Fiore-Gartland, David Goldblatt, Peter B. Gilbert, George R. Siber, Peter Dull, Stanley A. Plotkin
doi: https://doi.org/10.1101/2021.03.17.20200246
Kristen A. Earle
1Bill & Melinda Gates Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna M. Ambrosino
2Independent Advisor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Fiore-Gartland
3Fred Hutchinson Cancer Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew Fiore-Gartland
David Goldblatt
4University College London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter B. Gilbert
3Fred Hutchinson Cancer Research Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George R. Siber
2Independent Advisor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Dull
1Bill & Melinda Gates Foundation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: peter.dull@gatesfoundation.org
Stanley A. Plotkin
5University of Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Though eleven novel COVID-19 vaccines have demonstrated efficacy, additional affordable, scalable, and deliverable vaccines are needed to meet unprecedented global demand. With placebo-controlled efficacy trials becoming infeasible due to the roll out of licensed vaccines, a correlate of protection is urgently needed to provide a path for regulatory approval of novel vaccines. To assess whether antibody titers may reasonably predict efficacy, we evaluated the relationship between efficacy and in vitro neutralizing and binding antibodies of 7 vaccines for which sufficient data have been generated. Once calibrated to titers of human convalescent sera reported in each study, a robust correlation was seen between neutralizing titer and efficacy (ρ= 0.79) and binding antibody titer and efficacy (ρ = 0.93), despite geographically diverse study populations subject to different forces of infection and circulating variants, and use of different endpoints, assays, convalescent sera panels and manufacturing platforms. This correlation is strengthened by substituting post-hoc analyses for efficacy against the ancestral strain (D614G), where available. Together with an accumulating body of evidence from natural history studies and animal models, these results support the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

Competing Interest Statement

Dr. Plotkin consults for Janssen and Moderna; Dr. Siber reports personal fees from Clover, other from COVAXX, personal fees from CanSino, personal fees from CureVac, personal fees from Valneva, personal fees and other from Affinivax, outside the submitted work; Dr. Gilbert reports grants and non-financial support from SanofiPasteur, outside the submitted work; Dr. Ambrosino reports personal fees from Covaxx, personal fees from Clover Biopharmaceuticals, outside the submitted work.

Clinical Trial

N/A

Funding Statement

The authors received no financial support for the research or authorship of this article.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data sharing is not applicable to this article as no new data were created or analyzed in this study. All clinical data included in the analysis are in the public domain.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evidence for antibody as a protective correlate for COVID-19 vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evidence for antibody as a protective correlate for COVID-19 vaccines
Kristen A. Earle, Donna M. Ambrosino, Andrew Fiore-Gartland, David Goldblatt, Peter B. Gilbert, George R. Siber, Peter Dull, Stanley A. Plotkin
medRxiv 2021.03.17.20200246; doi: https://doi.org/10.1101/2021.03.17.20200246
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evidence for antibody as a protective correlate for COVID-19 vaccines
Kristen A. Earle, Donna M. Ambrosino, Andrew Fiore-Gartland, David Goldblatt, Peter B. Gilbert, George R. Siber, Peter Dull, Stanley A. Plotkin
medRxiv 2021.03.17.20200246; doi: https://doi.org/10.1101/2021.03.17.20200246

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8783)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1861)
  • Geriatric Medicine (178)
  • Health Economics (388)
  • Health Informatics (1291)
  • Health Policy (644)
  • Health Systems and Quality Improvement (491)
  • Hematology (207)
  • HIV/AIDS (394)
  • Infectious Diseases (except HIV/AIDS) (10557)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1754)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (461)
  • Oncology (964)
  • Ophthalmology (282)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1843)
  • Public and Global Health (3983)
  • Radiology and Imaging (654)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)